Tablet press investment at Juniper Pharma Services

Ian Lafferty at Juniper Pharma Services

Latest addition to the company's suite of tablet manufacturing equipment enables the CDMO to produce single and bi-layer tablets in multiple tooling formats.

The investment by the UK-based contract development and manufacturing organisation (CDMO) significantly extends its tablet production capacity and further strengthens the company’s ability to support clients’ clinical needs.

Its new RoTab tablet press by kg-pharma is designed specifically for batch sizes from 50g to 50kg and allows Juniper Pharma Services to produce up to 42,000 tablets per hour. This latest addition to its suite of tablet manufacturing equipment enables the CDMO to produce single and bi-layer tablets in multiple tooling formats.

The tablet press is the latest in a string of recent equipment investments by the CDMO and comes just weeks after the company announced significant expansion to its spray drying, topical, and semi-solid capabilities.

Ian Lafferty, VP of operations at Juniper Pharma Services, said: “The installation of this additional tablet press machine takes both our capability to produce different tablet types, and our output capacity, to a new level.

“This fully instrumented machine provides real time compression data, allowing our team to provide invaluable understanding during the optimisation of clients’ tablet formulations, enabling a smooth transition from pilot scale to commercial high speed tablet manufacturing.”

Juniper Pharma Services develops and produces oral and topical drug products for clinical trials and is able to optimise formulation performance through its team’s science-led approach to projects.

Dr Lafferty added: “We continue to expand our support to pharmaceutical and biotechnology companies across the globe, especially to those with significant formulation challenges requiring the integrated skills of a problem-to-solution minded development team.

“Our recent investments have strategically expanded and extended our development and manufacturing capabilities to ensure we are equipped to support drug development at a clinical scale, while also giving a commercially robust and replicable process.”